Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGRN-305 in moderate to severe hidradenitis suppurativa
NCT05286567Phase 1Completed
- Sponsor
- Aarhus University Hospital
- Start
- Sep 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing RGRN-305 with Placebo (2 arms). Primary endpoint: Hidradenitis Suppurativa Clinical Response 50 at 16 weeks. Started Sep 2021; status: completed.
02
Drugs
cudc-305
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05286567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286567.